AC Immune Advances ACI-24 Alzheimer’s Trial Expansion
LAUSANNE, Switzerland, April 2026 AC Immune SA announced continued progress in its Phase 1b/2 ABATE clinical trial evaluating ACI-24,...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
LAUSANNE, Switzerland, April 2026 AC Immune SA announced continued progress in its Phase 1b/2 ABATE clinical trial evaluating ACI-24,...
